Brief: Cantargia Reports New Results From Studies Investigating Nadunolimab

Cantargia AB

28/10/2024 13:58

Oct 28 (Reuters) - Cantargia AB  CANTA.ST :
    * REPORTS NEW RESULTS FROM CLINICAL STUDIES INVESTIGATING NADUNOLIMAB IN SEVERAL FORMS OF
CANCER;
SUPPORTING ONGOING STRATEGIES
    * NO UNEXPECTED SAFETY FINDINGS WERE OBSERVED.
    * NADUNOLIMAB APPEARED TO COUNTERACT OXALIPLATIN INDUCED PERIPHERAL NEUROPATHY

Source text:  ID:nMFN2CVHXr 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))